留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

1例帕金森病伴部分精神障碍患者的用药分析和药学监护

徐栋丽,  应茵,  陆绪亮,  宋洪涛,  戴海斌

downloadPDF
文章导航 > 药学实践与服务  > 2017 >  35(5): 460-462,465
徐栋丽, 应茵, 陆绪亮, 宋洪涛, 戴海斌. 1例帕金森病伴部分精神障碍患者的用药分析和药学监护[J]. 药学实践与服务, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
引用本文: 徐栋丽, 应茵, 陆绪亮, 宋洪涛, 戴海斌. 1例帕金森病伴部分精神障碍患者的用药分析和药学监护[J]. 药学实践与服务, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
shu
XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
Citation: XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
shu

1例帕金森病伴部分精神障碍患者的用药分析和药学监护

doi: 10.3969/j.issn.1006-0111.2017.05.019
  • 1.

    浙江省立同德医院, 浙江 杭州 310000

  • 2.

    福州总医院药学科, 福建 福州 350025

  • 3.

    浙江大学医学院附属第二医院药剂科, 浙江 杭州 310009

Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders

  • 1.

    Department of Pharmacy, Zhejiang Province Tongde Hospital, Hangzhou 310000, China

  • 2.

    Department of Pharmacy, Fuzhou General Hospital, Fuzhou 350025, China

  • 3.

    Department of Pharmacy, Second Hospital Affiliated to College of Medicinal Sciences, Zhejiang University, Hangzhou 310009, China

  • 摘要: 目的 探讨临床药师在帕金森病伴部分精神障碍患者治疗过程中的作用。 方法 临床药师结合患者疾病特点、用药史、药物相互作用及药品不良反应等情况，对患者进行药学监护并提出优化治疗方案的建议。 结果 临床药师参与患者治疗方案的制订，进行用药指导和出院教育，促进合理用药。 结论 临床药师可利用自身专业知识，积极参与临床药物治疗工作，协同医师优化临床给药方案。
    Abstract: Objective To investigate the role of clinical pharmacists in the treatment of a Parkinson's disease patient with mental disorders. Methods Clinical pharmacists provided appropriate pharmaceutical care and optimized the treatment program based on patient's symptom, medication history, drug interactions,and adverse drug reactions etc. Results Clinical pharmacists improved rational drug use by participating in the development of patient's treatment program, giving patient with proper medication instruction and discharge education. Conclusion With their professional knowledge, clinical pharmacists play an important role in rational drug use and helping physicians to optimize the medication regimen.
  • [1] 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第三版)［J］. 中华神经科杂志, 2014, 47(6):428-433.
    [2] 王惠霞,武新安,何忠芳. 帕金森病一例药学监护实践［J］. 临床合理用药杂志, 2012,12(5): 85-86.
    [3] Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines［S］. Neurology, 2001,56(11): S1-S88.
    [4] 刘春风,尹伟华,罗蔚锋.帕金森病患者运动障碍和症状波动的影响因素［J］.中华神经科杂志,2003, 36(6): 411-413.
    [5] Zhang ZX, Chen H, Chen SD, et al.Chinese culture permeation in the treatment of Parkinson disease:a cross-sectional study in four regions of China［J］. BMC Res Notes, 2014, 7: 65.
    [6] Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease［J］. Mov Disord, 2013, 28(8):1064-1071.
    [7] 中华医学会神经病学分会神经心理学与行为神经病学组, 中华医学会神经病学分会神经心理学与行为神经病学组. 帕金森病抑郁、焦虑及精神病性障碍的诊断标准及治疗指南［J］.中华神经科杂志,2013,46(1):56-60.
    [8] 江开达.中华医学会精神科分会.抑郁障碍防治指南［M］.北京:北京大学医学出版社,2007:21.
    [9] Barone P,Poewe W,Albrecht S,et al.Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease:a randomised,double-blind,Placebo-controlled trial［J］.Lancet Neurol,2010,9(6):573-580.
    [10] O'Sullivan SS, Williams DR, Gallagher DA, et al. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study［J］. Mov Disord, 2008, 23(1): 101-106.
    [11] Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms［J］. Mov Disord, 2014, 29(2):195-202.
    [12] Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study［J］. Mov Disord, 2000,15(4): 669-677.
    [13] Leentjens AF, Van den Akker M, Metsemakers JF, et al. Higher incidence of depression preceding the onset of Parkinson's disease: a register study［J］. Mov Disord, 2003,18(4): 414-418.
    [14] Gonera EG, van't Hof M, Berger HJ, et al. Symptoms and duration of the prodromal phase in Parkinson's disease［J］. Mov Disord, 1997,12(6): 871-876.
    [15] Shen CC,Tsai SJ, Perng CL, et al. Risk of Parkinson disease after depression: a nationwide population-based study［J］. Neurology,2013, 81(17): 1538-1544.
    [16] Breier A, Sutton V, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease［J］. Biol Psychiatry,2002, 52(5): 438-445.
    [17] Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatnlent for dopaminergic-induced hallucinations［J］. Mov Disord, 2002, 17(5):1031-1035.
    [18] Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine:comparative effects on motor function in hallucinating PD patients［J］. Neurology,2000, 55(6): 789-794.
    [19] Friedman JH. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease［J］. Neuorlogy,1998, 50(4):1195-1196.
    [20] Seppi K, Weintraub D, Coelho M, et a1. The movement disorder society evidence-based medicine review update:treatments for the non-motor symptoms of Parkinson's disease［J］. Mov Disord,2011, 26(3): S42-80.
  • [1] 徐璐璐, 刘爱军.  丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2024, 42(12): 1-8. doi: 10.12206/j.issn.2097-2024.202312027
    [2] 石晓萍, 吕迁洲, 李晓宇, 许青.  泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
    [3] 陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾.  基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
    [4] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
    [5] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2997
  • HTML全文浏览量:  299
  • PDF下载量:  1012
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-03-03
  • 修回日期:  2016-09-06

1例帕金森病伴部分精神障碍患者的用药分析和药学监护

doi: 10.3969/j.issn.1006-0111.2017.05.019
  • 1. 浙江省立同德医院, 浙江 杭州 310000
  • 2. 福州总医院药学科, 福建 福州 350025
  • 3. 浙江大学医学院附属第二医院药剂科, 浙江 杭州 310009
  • 收稿日期: 2016-03-03
  • 修回日期: 2016-09-06

摘要: 目的 探讨临床药师在帕金森病伴部分精神障碍患者治疗过程中的作用。 方法 临床药师结合患者疾病特点、用药史、药物相互作用及药品不良反应等情况，对患者进行药学监护并提出优化治疗方案的建议。 结果 临床药师参与患者治疗方案的制订，进行用药指导和出院教育，促进合理用药。 结论 临床药师可利用自身专业知识，积极参与临床药物治疗工作，协同医师优化临床给药方案。

English Abstract

徐栋丽, 应茵, 陆绪亮, 宋洪涛, 戴海斌. 1例帕金森病伴部分精神障碍患者的用药分析和药学监护[J]. 药学实践与服务, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
引用本文: 徐栋丽, 应茵, 陆绪亮, 宋洪涛, 戴海斌. 1例帕金森病伴部分精神障碍患者的用药分析和药学监护[J]. 药学实践与服务, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
shu
XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
Citation: XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
shu

    全文HTML

参考文献 (20)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计